$6.18
10.64% yesterday
Nasdaq, Nov 15, 10:19 pm CET
ISIN
US75629V1044
Symbol
RXRX
Sector
Industry

Recursion Pharmaceuticals Stock price

$6.18
-0.50 7.42% 1M
-3.84 38.31% 6M
-3.69 37.37% YTD
-1.01 14.00% 1Y
-12.58 67.07% 3Y
-25.13 80.27% 5Y
-25.13 80.27% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.74 10.64%
ISIN
US75629V1044
Symbol
RXRX
Sector
Industry

Key metrics

Market capitalization $1.77b
Enterprise Value $1.43b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 21.96
P/S ratio (TTM) P/S ratio 27.16
P/B ratio (TTM) P/B ratio 3.37
Revenue growth (TTM) Revenue growth 37.64%
Revenue (TTM) Revenue $65.18m
EBIT (operating result TTM) EBIT $-404.37m
Free Cash Flow (TTM) Free Cash Flow $-332.29m
Cash position $429.20m
EPS (TTM) EPS $-1.53
P/E forward negative
P/S forward 32.40
EV/Sales forward 26.86
Short interest 24.56%
Show more

Is Recursion Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Recursion Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Recursion Pharmaceuticals forecast:

2x Buy
25%
6x Hold
75%

Analyst Opinions

8 Analysts have issued a Recursion Pharmaceuticals forecast:

Buy
25%
Hold
75%

Financial data from Recursion Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
65 65
38% 38%
100%
- Direct Costs 67 67
38% 38%
103%
-2.14 -2.14
44% 44%
-3%
- Selling and Administrative Expenses 92 92
25% 25%
142%
- Research and Development Expense 271 271
29% 29%
415%
-365 -365
28% 28%
-560%
- Depreciation and Amortization 39 39
50% 50%
60%
EBIT (Operating Income) EBIT -404 -404
30% 30%
-620%
Net Profit -378 -378
29% 29%
-580%

In millions USD.

Don't miss a Thing! We will send you all news about Recursion Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Recursion Pharmaceuticals Stock News

Neutral
GlobeNewsWire
2 days ago
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close
Neutral
GlobeNewsWire
3 days ago
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler
Positive
The Motley Fool
14 days ago
In an environment where the typical small biotech name is riskier than not, this one is curiously different.
More Recursion Pharmaceuticals News

Company Profile

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Chistopher Gibson
Founded 2013
Website www.recursion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today